Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration

被引：17
|
作者：
Darmon, Michael [1 ]
Guichard, Isabelle [1 ]
Vincent, Francois [2 ]
机构：
[1] St Etienne Teaching Hosp, St Etienne, France
[2] Avicenne Teaching Hosp, Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 03期
关键词：
SINGLE-DOSE RASBURICASE; 6; MG; ADULTS; HYPERURICEMIA; PROPHYLAXIS; MANAGEMENT; CANCER;
D O I：
10.1200/JCO.2010.32.6751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [21] The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome
    Boutin, Alyssa
    Blackman, Alison
    O'Sullivan, David M.
    Forcello, Nicholas
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 577 - 583
  • [22] Tumor Lysis Syndrome
    Williams, Shelly M.
    Killeen, Anthony A.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2019, 143 (03) : 386 - 393
  • [23] Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings
    Abousaud, Marin, I
    Rush, Marie C.
    Rockey, Michelle
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1165 - 1171
  • [24] Spontaneous Tumor Lysis Syndrome
    Wesemueller, Wiebke
    Taverna, Christian
    CASE REPORTS IN ONCOLOGY, 2020, 13 (03): : 1116 - 1124
  • [25] A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
    Vadhan-Raj, S.
    Fayad, L. E.
    Fanale, M. A.
    Pro, B.
    Rodriguez, A.
    Hagemeister, F. B.
    Bueso-Ramos, C. E.
    Zhou, X.
    McLaughlin, P. W.
    Fowler, N.
    Shah, J.
    Orlowski, R. Z.
    Samaniego, F.
    Wang, M.
    Cortes, J. E.
    Younes, A.
    Kwak, L. W.
    Sarlis, N. J.
    Romaguera, J. E.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1640 - 1645
  • [26] Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era
    Toda, Yumiko
    Ashizawa, Masahiro
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-Ichiro
    Nagayama, Takashi
    Umino, Kento
    Minakata, Daisuke
    Morita, Kaoru
    Yamamoto, Chihiro
    Hatano, Kaoru
    Sato, Kazuya
    Fujiwara, Shin-Ichiro
    Ohmine, Ken
    Kanda, Yoshinobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 660 - 666
  • [27] Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
    McBride, Ali
    Westervelt, Peter
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [28] Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options
    Kikuchi, Shohei
    Muro, Makiko
    Kamihara, Yusuke
    Wada, Akinori
    Murakami, Jun
    Nabe, Yoshimi
    Minemura, Tomoki
    Sato, Tsutomu
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2023, 12 (01) : 69 - 74
  • [29] A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults
    Hossain, Shahrier
    Naber, Martha
    Yacobucci, Matthew J.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (06) : 1326 - 1331
  • [30] Rasburicase-Induced Falsely Low Measurement of Uric Acid in Tumor Lysis Syndrome: A Report of Two Cases
    Yu, Lian
    Xie, Yinjing
    Ma, Jiangtao
    Li, Guoqiang
    Yuan, Xiaopeng
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
12345